This review summarizes recent advances in the understanding of metabolic pathways involved in familial combined hyperlipidaemia, a common inherited condition linked to premature myocardial infarction.
Answers are grounded in this paper and cite their sources.
Metabolic pathway advances in familial combined hyperlipidaemia should not yet alter management; leaves open targeted therapy trials.
Familial combined hyperlipidaemia is the most common inherited hyperlipidaemia and is found in up to 10% of patients with premature myocardial infarction. The genetic and metabolic bases of the disorder have not yet been defined. This review discusses the important advances in the past year in our understanding of the different metabolic pathways contributing to the pathogenesis of familial combined hyperlipidaemia.
No takes yet. Share an insight, caveat, or question.
Graaf et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: